A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Herlev Hospital
Brown University
Molecular Templates, Inc.
Sumitomo Pharma America, Inc.
Fate Therapeutics
pharmaand GmbH
Duke University
National Cancer Centre, Singapore
ExcellaBio LLC
University of Chicago